Sang Gyune Kim

Quick facts

Phase 2 pipeline

• Daclatasvir and Asunaprevir · Infectious Disease
  Daclatasvir and Asunaprevir are direct-acting antivirals that inhibit the HCV NS5A and NS3/4A proteases, respectively.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sang Gyune Kim portfolio CI brief
• Sang Gyune Kim pipeline updates RSS